By Sam van de Schootbrugge 14-04-2021
In: hive-exclusives | COVID-19

Weekly Vaccination Update: J&J Pause and EU Supply Schedule

(1 min read)
Resize text:

In this prime tracker, we review the latest vaccine developments globally. This week, we’ve added some brief commentary on the Johnson & Johnson vaccine pause and the EU’s Q2 supply schedule. On the details:

Global Outlook (Charts 1, 2, 4 & 5):

  • This week, an average of 17.7mn vaccinations were administered globally every day, up 10% WoW (Chart 1). European countries in particular performed well, although a larger share of North America’s population has been vaccinated over the week (Chart 2). In all, 5.8% of the world’s population have now received at least one vaccination dose, up from 4.9% last week, and an estimated 3.5% have immunity to Covid-19.
  • On the Johnson & Johnson vaccine distribution delay, the US and South Africa will see an immediate impact. From mid-April to end of May, a third of the US vaccine supply was expected to be made up of the J&J vaccine (Chart 4). Every day lost, will likely mean 730,000 fewer daily doses for the US in April. The EU was also due to receive its first batch in mid-April, and 55mn doses were expected in Q2 – 13.5% of overall supply.

Share of Population Vaccinated:

  • European countries, Argentina and India set the pace this week. Hungary vaccinated 5.6% of its population– the largest WoW increase on the list. Also, the population shares that received at least one dose in Spain, Germany and Poland increased by at least a quarter WoW. The same is true for Argentina and India, where 2.4% and 1.7% of their respective populations received a dose this week.
  • At the bottom of the list, South Africa has fully vaccinated 0.5% of its population, largely unchanged WoW. Thailand, on the other hand, more than doubled the share of its population that has received their first dose. Interestingly, Canada’s rollout is currently heavily skewed towards administering the first of a two-dose protocol. Meanwhile, the UK has seen a large WoW rise in the share of fully vaccinated individuals – 11.3% have now received their second dose, up from 8% last week.

Doses (Charts 3 & 5):

  • Almost all countries expanded vaccination rollouts this week, with Israel, the UK, Turkey, Switzerland, Malaysia and South Africa being the only countries whose daily average doses fell WoW. The largest increases were in Thailand, New Zealand, Hong Kong and Russia. On a population-adjusted basis, Hungary is administering more doses per 100k than any other country on the list. Next is the US, followed by Chile.
  • European countries performed particularly well this week. Across the EU, average daily doses are up 34% WoW to 2.1mn. Germany and Spain led the way, and the latter is now vaccinating at a faster per-head-of-population rate than the UK. Supply is also set to increase. Excluding J&J and with the latest 50mn supply boost from Pfizer and BioNTech, 355mn doses are expected to be supplied to the EU in Q2, over a three-fold increase from Q1 (Chart 5). This could push daily doses up to an average of 3.9mn doses a day in Q2, but at the current level of uptake is more likely to be 2.8mn. On a population-adjusted basis, this is still just 60% of the current US vaccination rate.


  • Immunity is gained either via the vaccine (blue) or via infection over the last 6 months (orange). Following the large vaccination drive in the UK three weeks ago, the country’s immunity total is 48.2%, up from 43.1% last week. Yet, the recent slowdown has pushed the 80% target back to September 2021. The Czech Republic ranks fifth on total immunity, despite having lower vaccination shares. This is because an estimated 17% have had the virus over the last 6 months.
  • Projecting the current two-week vaccination rates forward, Hungary is now set to reach herd immunity by June. The EU’s date has also been pulled forward from Jan 2022 to Nov 2021. The US and Chile are still on target to reach 80% immunity by July.





Sam van de Schootbrugge is a macro research economist taking a one year industrial break from his Ph.D. in Economics. He has 2 years of experience working in government and has an MPhil degree in Economic Research from the University of Cambridge. His research expertise are in international finance, macroeconomics and fiscal policy.
(The commentary contained in the above article does not constitute an offer or a solicitation, or a recommendation to implement or liquidate an investment or to carry out any other transaction. It should not be used as a basis for any investment decision or other decision. Any investment decision should be based on appropriate professional advice specific to your needs.)

For access to our Slack Chat Room, where we discuss all things markets with our researchers and subscribers



Weekly Vaccination Update: US Vaccination Rates Face Largest Setback Yet (3 min read)

By Sam van de Schootbrugge | Apr 28, 2021
This week, an average of 16.6mn vaccinations were administered globally every day, up 1% WoW. The largest improvements were...

India’s Local Lockdowns Trigger a Sharp Slowdown in Mobility (2 min read)

By Caroline Grady | Apr 27, 2021
Six consecutive days of above 300,000 new COVID cases are taking their toll. On Sunday, Delhi extended its six-day lockdown...

Worrying About Biden’s Capital Gains Tax Headline? Don’t! (2 min read)

By John Tierney | Apr 23, 2021
Talk about horrible headlines. President Joe Biden wants to boost the capital gains tax to 39.6% for people making more than $1 million...


Why Growth Stocks Are Looking Good Again (4 min read)

By John Tierney | Apr 26, 2021
Summary In equity markets, the 2021 storylines…

FOMC Preview: All About Taper Timing (2 min read)

By Jon Turek | Apr 27, 2021
Summary Market focus ahead of Wednesday’s FOMC…

Five Things You Did Not Know About China (2 min read)

By Bilal Hafeez | Apr 13, 2021
China is a global economic superpower, yet…

Want To Join Our Community Of Leading Investors And Researchers In Our Slack Chat Room?